We use cookies for a better user experience. Read our Privacy Policy

I Agree

Viral Vector & Plasmid DNA Manufacturing Market

Viral Vector & Plasmid DNA Manufacturing Market (Type: Lentivirus, Adenovirus Adeno-associated Virus (AAV), Plasmid DNA, and Others; Application: Gene Therapy, Vaccinology, and Others; Disease: Genetic Disorders, Cancer, Infectious Diseases, and Others; End-user: Biotech Companies and Research Institutes) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027

Global Viral Vector & Plasmid DNA Manufacturing Market: Overview

  • This report analyzes the current scenario and future growth prospects of the global viral vector & plasmid DNA manufacturing market
  • The report provides an elaborate executive summary, which provides a snapshot of various segments of the global viral vector & plasmid DNA manufacturing market. It also provides information and data analysis of the global viral vector & plasmid DNA manufacturing market with respect to segments based on product, application, end-user, and region.
  • The overview section of the report provides a detailed qualitative analysis of drivers, restraints, and opportunities that impact the global viral vector & plasmid DNA manufacturing market
  • The report includes company profiles, which provide information about business strategies, product portfolios, and financials of players operating in the global viral vector & plasmid DNA manufacturing market and competition landscape of the market
  • The report on the global viral vector & plasmid DNA manufacturing market offers attractiveness analysis of different segments of the market across regions
  • The last section of the report comprises quantitative and qualitative analysis on market share/position of key players operating in the global viral vector & plasmid DNA manufacturing market. It analyzes key competitive strategies adopted by major market players, thereby presenting a thorough understanding of the competition scenario in the global viral vector & plasmid DNA manufacturing market.
global viral vector plasmid dna manufacturing market revenue share by region

To know the scope of our report Get a Sample on Point-of-Care Viral vector & Plasmid DNA Manufacturing Market

Global Viral Vector & Plasmid DNA Manufacturing Market: Key Segments

  • In terms of type, the global viral vector & plasmid DNA manufacturing market can be classified into lentivirus, adenovirus, adeno-associated virus (AAV), plasmid DNA, and others. The plasmid DNA segment accounted for major market share in 2018.
  • Increase in awareness about gene therapy and technological advancements in the production of plasmid DNA are projected to fuel the growth of the plasmid DNA segment during the forecast period
  • Based on application, the global viral vector & plasmid DNA manufacturing market has been segmented into gene therapy, vaccinology, and others
  • The gene therapy segment accounted for the largest market share in 2018. Growth of the segment can be attributed to rich product pipeline and increase in the number of companies manufacturing vector-based products for gene therapies.
  • In terms of disease, the global viral vector & plasmid DNA manufacturing market has been categorized into genetic disorders, cancer, infectious diseases, and others
  • The cancer segment accounted for the largest market share in 2018. Growth of the segment can be attributed to high prevalence of cancer and increased acceptance of gene therapy for the treatment of cancer.
  • Based on end-user, the global viral vector & plasmid DNA manufacturing market has been bifurcated into biotech companies and research institutes. The biotech companies segment accounted for major market share in 2018 and the trend is projected to continue in the near future. The biotech companies segment is anticipated to witness significant growth, owing to increase in investment by biotech companies in vector-based technologies and high demand for new therapies.
  • Market size and forecast for each of the segments of the global viral vector & plasmid DNA manufacturing market have been provided for the period from 2017 to 2027. The CAGRs of the segments of the global viral vector & plasmid DNA manufacturing market have also been provided for the period from 2019 to 2027, considering 2018 as the base year.

Get a glimpse of the in-depth analysis through our Report Brochure

Global Viral Vector & Plasmid DNA Manufacturing Market: Regional Outlook

  • In terms of region, the global viral vector & plasmid DNA manufacturing market has been segmented into North America (U.S. and Canada), Europe (U.K., Germany, Spain, Italy, France, and Rest of Europe), Asia Pacific (China, India, Japan, Australia & New Zealand, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), and Middle East & Africa (GCC Countries, South Africa, and Rest of Middle East & Africa). Each region of the global viral vector & plasmid DNA manufacturing market has been divided into countries/sub-regions.
  • The report provides size and forecast of the global viral vector & plasmid DNA manufacturing market in each region and country/sub-region for the period from 2017 to 2027. The CAGR for the market in each of these regions and countries/sub-regions has also been provided for the period from 2019 to 2027. The study also covers the market competition scenario in these regions. 

Expanding operations in future? To get the perfect launch ask for a custom report 

Companies Covered in Report on Global Viral Vector & Plasmid DNA Manufacturing Market

  • Key players in the global viral vector & plasmid DNA manufacturing market have been profiled based on attributes such as company overview, product portfolio, financial overview, recent developments, and competitive business strategies
  • Major companies profiled in the global viral vector & plasmid DNA manufacturing market report are
    • CobraBiologics
    • Novasep, Inc.
    • Cell and Gene Therapy Catapult
    • Kaneka Eurogentec S.A.
    • FUJIFILM Diosynth Biotechnologies, Inc.
    • Spark Therapeutics, Inc.
    • Merck KGaA
    • uniQure N.V.
    • Lonza

Global Viral Vector & Plasmid DNA Manufacturing Market - Segmentation

Type

Lentivirus

Adenovirus

Adeno-associated Virus (AAV)

Plasmid DNA

Others

Application

Gene Therapy

Vaccinology

Others

Disease

Genetic Disorders

Cancer

Infectious Diseases

Others

End-user

Biotech Companies

Research Institutes

Region

North America

Europe

Asia Pacific

Latin America

Middle East & Africa

Viral Vector & Plasmid DNA Manufacturing Market

Interested in this report?
Get a FREE Brochure now!

Get Free Brochure

*Get Brochure Report (PDF) sent to your email within minutes

Frequently Asked Questions

What is the total market worth of viral vector & plasmid DNA manufacturing market?

Viral vector & plasmid DNA manufacturing market to reach US$ 2.3 Bn by 2027

What is the anticipated CAGR of the viral vector & plasmid DNA manufacturing market in the forecast period?

Viral vector & plasmid DNA manufacturing market is projected to expand at a CAGR of 23.3% from 2019 to 2027

What are the key driving factors for the growth of the viral vector & plasmid DNA manufacturing market?

Viral vector & plasmid DNA manufacturing market is driven by increase in awareness about viral vector-based treatments

Which is the rising prominent segment in the viral vector & plasmid DNA manufacturing market?

The plasmid DNA segment dominated the global viral vector & plasmid DNA manufacturing market and the trend is expected to continue during the forecast period

Who are the key players in the viral vector & plasmid DNA manufacturing market?

Key players in the global viral vector & plasmid DNA manufacturing market include CobraBiologics, Novasep Inc., Cell and Gene Therapy Catapult, Kaneka Eurogentec S.A., FUJIFILM Diosynth Biotechnologies, Inc.

1. Preface 

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Viral Vector & Plasmid DNA Manufacturing Market

4. Market Overview

    4.1. Introduction

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global Viral Vector & Plasmid DNA Manufacturing Market Analysis and Forecast, 2017–2027

5. Market Outlook

    5.1. Evolution of Gene Therapy

    5.2. Key Mergers & Acquisitions

    5.3. Pipeline Analysis

    5.4. List of Manufacturers, by Location of Manufacturing Facility & Type of Vector Production 

6. Global Viral Vector & Plasmid DNA Manufacturing Market Value and Forecast, by Type

    6.1. Introduction 

    6.2. Global Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by Type, 2017–2027

        6.2.1. Lentivirus

        6.2.2. Adenovirus 

        6.2.3. Adeno-associated Virus (AAV)

        6.2.4. Plasmid DNA

        6.2.5. Others 

    6.3. Global Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by Type

7. Global Viral Vector & Plasmid DNA Manufacturing Market Value and Forecast, by Application

    7.1. Introduction 

    7.2. Global Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by Application, 2017–2027

        7.2.1. Gene Therapy

        7.2.2. Vaccinology

        7.2.3. Others 

    7.3. Global Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by Application

8. Global Viral Vector & Plasmid DNA Manufacturing Market Value and Forecast, by Disease

    8.1. Introduction 

    8.2. Global Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by Disease, 2017–2027

        8.2.1. Genetic Disorders

        8.2.2. Cancer

        8.2.3. Infectious Diseases

        8.2.4. Others

    8.3. Global Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by Disease

9. Global Viral Vector & Plasmid DNA Manufacturing Market Value and Forecast, by End-user

    9.1. Introduction 

    9.2. Global Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by End-user, 2017–2027

        9.2.1. Biotech Companies

        9.2.2. Research Institutes

    9.3. Global Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by End-user

10. Global Viral Vector & Plasmid DNA Manufacturing Market Value and Forecast, by Region

    10.1. Introduction 

    10.2  Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by Region, 2017–2027

        10.1.1. North America

        10.1.2. Europe

        10.1.3. Asia Pacific

        10.1.4. Latin America

        10.1.5. Middle East & Africa

    10.3. Global Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by Region

11. North America Viral Vector & Plasmid DNA Manufacturing Market Analysis and Forecast 

    11.1. Introduction

    11.2. North America Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by Type, 2017–2027

        11.2.1. Lentivirus

        11.2.2. Adenovirus 

        11.2.3. Adeno-associated Virus (AAV)

        11.2.4. Plasmid DNA

        11.2.5. Others

    11.3. North America Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by Application, 2017–2027

        11.3.1. Gene Therapy

        11.3.2. Vaccinology

        11.3.3. Others

    11.4. North America Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by Disease, 2017–2027

        11.4.1. Genetic Disorders

        11.4.2. Cancer

        11.4.3. Infectious Diseases

        11.4.4. Others

    11.5. North America Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by End-user, 2017–2027

        11.5.1. Biotech Companies

        11.5.2. Research Institutes

    11.6. North America Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by Country, 2017–2027

        11.6.1. U.S.

        11.6.2. Canada

    11.7. North America Viral Vector & Plasmid DNA Manufacturing Market Attractiveness Analysis

        11.7.1. By Type

        11.7.2. By Application

        11.7.3. By Disease

        11.7.4. By End-user

        11.7.5. By Country

12. Europe Viral Vector & Plasmid DNA Manufacturing Market Analysis and Forecast 

    12.1. Introduction

    12.2. Europe Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by Type, 2017–2027

        12.2.1. Lentivirus

        12.2.2. Adenovirus 

        12.2.3. Adeno-associated Virus (AAV)

        12.2.4. Plasmid DNA

        12.2.5. Others

    12.3. Europe Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by Application, 2017–2027

        12.3.1. Gene Therapy

        12.3.2. Vaccinology

        12.3.3. Others

    12.4. Europe Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by Disease, 2017–2027

        12.4.1. Genetic Disorders

        12.4.2. Cancer

        12.4.3. Infectious Diseases

        12.4.4. Others

    12.5. Europe Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by End-user, 2017–2027

        12.5.1. Biotech Companies

        12.5.2. Research Institutes

    12.6. Europe Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by Country/Sub-region, 2017–2027

        12.6.1. Germany

        12.6.2. U.K.

        12.6.3. France

        12.6.4. Spain

        12.6.5. Italy 

        12.6.6. Rest of Europe

    12.7. Europe Viral Vector & Plasmid DNA Manufacturing Market Attractiveness Analysis

        12.7.1. By Type

        12.7.2. By Application

        12.7.3. By Disease

        12.7.4. By End-user

        12.7.5. By Country/Sub-region

13. Asia Pacific Viral Vector & Plasmid DNA Manufacturing Market Analysis and Forecast 

    13.1. Introduction

    13.2. Asia Pacific Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by Type, 2017–2027

        13.2.1. Lentivirus

        13.2.2. Adenovirus 

        13.2.3. Adeno-associated Virus (AAV)

        13.2.4. Plasmid DNA

        13.2.5. Others

    13.3. Asia Pacific Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by Application, 2017–2027

        13.3.1. Gene Therapy

        13.3.2. Vaccinology

        13.3.3. Others

    13.4. Asia Pacific Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by Disease, 2017–2027

        13.4.1. Genetic Disorders

        13.4.2. Cancer

        13.4.3. Infectious Diseases

        13.4.4. Others

    13.5. Asia Pacific Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by End-user, 2017–2027

        13.5.1. Biotech Companies

        13.5.2. Research Institutes

    13.6. Asia Pacific Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by Country/Sub-region, 2017–2027

        13.6.1. Japan

        13.6.2. China

        13.6.3. India

        13.6.4. Australia & New Zealand

        13.6.5. Rest of Asia Pacific

    13.7. Asia Pacific Viral Vector & Plasmid DNA Manufacturing Market Attractiveness Analysis

        13.7.1. By Type

        13.7.2. By Application

        13.7.3. By Disease

        13.7.4. By End-user

        13.7.5. By Country/Sub-region

14. Latin America Viral Vector & Plasmid DNA Manufacturing Market Analysis and Forecast 

    14.1. Introduction

    14.2. Latin America Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by Type, 2017–2027

        14.2.1. Lentivirus

        14.2.2. Adenovirus 

        14.2.3. Adeno-associated Virus (AAV)

        14.2.4. Plasmid DNA

        14.2.5. Others

    14.3. Latin America Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by Application, 2017–2027

        14.3.1. Gene Therapy

        14.3.2. Vaccinology

        14.3.3. Others

    14.4. Latin America Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by Disease, 2017–2027

        14.4.1. Genetic Disorders

        14.4.2. Cancer

        14.4.3. Infectious Diseases

        14.4.4. Others

    14.5. Latin America Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by End-user, 2017–2027

        14.5.1. Biotech Companies

        14.5.2. Research Institutes

    14.6. Latin America Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by Country/Sub-region, 2017–2027

        14.6.1. Brazil

        14.6.2. Mexico

        14.6.3. Rest of Latin America

    14.7. Latin America Viral Vector & Plasmid DNA Manufacturing Market Attractiveness Analysis

        14.7.1. By Type

        14.7.2. By Application

        14.7.3. By Disease

        14.7.4. By End-user

        14.7.5. By Country/Sub-region

15. Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Market Analysis and Forecast 

    15.1. Introduction

    15.2. Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by Type, 2017–2027

        15.2.1. Lentivirus

        15.2.2. Adenovirus 

        15.2.3. Adeno-associated Virus (AAV)

        15.2.4. Plasmid DNA

        15.2.5. Others

    15.3. Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by Application, 2017–2027

        15.3.1. Gene Therapy

        15.3.2. Vaccinology

        15.3.3. Others

    15.4. Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by Disease, 2017–2027

        15.4.1. Genetic Disorders

        15.4.2. Cancer

        15.4.3. Infectious Diseases

        15.4.4. Others

    15.5. Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by End-user, 2017–2027

        15.5.1. Biotech Companies

        15.5.2. Research Institutes

    15.6. Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by Country/Sub-region, 2017–2027

        15.6.1. GCC Countries

        15.6.2. South Africa

        15.6.3. Rest of Middle East & Africa

    15.7. Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Market Attractiveness Analysis

        15.7.1. By Type

        15.7.2. By Application

        15.7.3. By Disease

        15.7.4. By End-user

        15.7.5. By Country/Sub-region

16. Competitive Landscape

    16.1.  Market Player -- Competition Matrix (By Tier and Size of companies)

    16.2.  Company Profiles

        16.2.1. Lonza

            16.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.1.2. Product Portfolio

            16.2.1.3. SWOT Analysis

            16.2.1.4. Financial Overview

            16.2.1.5. Strategic Overview

        16.2.2. Catapult 

            16.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.2.2. Product Portfolio

            16.2.2.3. SWOT Analysis

            16.2.2.4. Financial Overview

            16.2.2.5. Strategic Overview

        16.2.3. uniQure N.V.

            16.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.3.2. Product Portfolio

            16.2.3.3. SWOT Analysis

            16.2.3.4. Financial Overview

            16.2.3.5. Strategic Overview

        16.2.4. FUJIFILM Diosynth Biotechnologies

            16.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.4.2. Product Portfolio

            16.2.4.3. SWOT Analysis

            16.2.4.4. Financial Overview

            16.2.4.5. Strategic Overview

        16.2.5. Kaneka Eurogentec S.A.

            16.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.5.2. Product Portfolio

            16.2.5.3. SWOT Analysis

            16.2.5.4. Financial Overview

            16.2.5.5. Strategic Overview

        16.2.6. Oxford Biomedica

            16.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.6.2. Product Portfolio

            16.2.6.3. SWOT Analysis

            16.2.6.4. Financial Overview

            16.2.6.5. Strategic Overview

        16.2.7. Spark Therapeutics, Inc.

            16.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.7.2. Product Portfolio

            16.2.7.3. SWOT Analysis

            16.2.7.4. Financial Overview

            16.2.7.5. Strategic Overview

        16.2.8. Cobrabiologics

            16.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.8.2. Product Portfolio

            16.2.8.3. SWOT Analysis

            16.2.8.4. Financial Overview

            16.2.8.5. Strategic Overview

        16.2.9. Merck KGaA

            16.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.9.2. Product Portfolio

            16.2.9.3. SWOT Analysis

            16.2.9.4. Financial Overview

            16.2.9.5. Strategic Overview

List of Tables

Table 01: Global Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast, by Type, 2017?2027

Table 02: Global Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast, by Application, 2017?2027

Table 03: Global Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast, by Disease, 2017?2027

Table 04: Global Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast, by End-user, 2017?2027

Table 05: Global Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast, by Region, 2017?2027

Table 06: North America Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast, by Country, 2017?2027

Table 07: North America Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast, by Type, 2017?2027

Table 08: North America Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast, by Application, 2017?2027

Table 09: North America Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast, by Disease, 2017?2027

Table 10: North America Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast, by End-user, 2017?2027

Table 11: Europe Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

Table 12: Europe Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast, by Type, 2017?2027

Table 13: Europe Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast, by Application, 2017?2027

Table 14: Europe Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast, by Disease, 2017?2027

Table 15: Europe Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast, by End-user, 2017?2027

Table 16: Asia Pacific Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

Table 17: Asia Pacific Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast, by Type, 2017?2027

Table 18: Asia Pacific Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast, by Application, 2017?2027

Table 19: Asia Pacific Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast, by Disease, 2017?2027

Table 20: Asia Pacific Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast, by End-user, 2017?2027

Table 21: Latin America Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

Table 22: Latin America Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast, by Type, 2017?2027

Table 23: Latin America Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast, by Application, 2017?2027

Table 24: Latin America Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast, by Disease, 2017?2027

Table 25: Latin America Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast, by End-user, 2017?2027

Table 26: Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

Table 27: Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast, by Type, 2017?2027

Table 28: Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast, by Application, 2017?2027

Table 29: Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast, by Disease, 2017?2027

Table 30: Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast, by End-user, 2017?2027

List of Figures

Figure 01: Global Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) and Distribution, by Region, 2018 and 2027

Figure 02: Global Viral Vector & Plasmid DNA Manufacturing Market Value, by Type, 2018(A) 

Figure 03: Global Viral Vector & Plasmid DNA Manufacturing Market Snapshot

Figure 04: Global Viral Vector & Plasmid DNA Manufacturing Market Value Share, by Type

Figure 05: Global Viral Vector & Plasmid DNA Manufacturing Market Value Share, by Application

Figure 06: Global Viral Vector & Plasmid DNA Manufacturing Market Value Share, by Disease

Figure 07: Global Viral Vector & Plasmid DNA Manufacturing Market Value Share, by End-user

Figure 08: Global Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017?2027

Figure 09: Global Viral Vector & Plasmid DNA Manufacturing Market Value Share, by Type, 2018

Figure 10: Global Viral Vector & Plasmid DNA Manufacturing Market Value Share, by End-user, 2018

Figure 11: Global Viral Vector & Plasmid DNA Manufacturing Market Value Share, by Region, 2018

Figure 12: Global Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by Type, 2019–2027

Figure 13: Global Viral Vector & Plasmid DNA Manufacturing Market Value Share, by Type, 2018 and 2027

Figure 14: Global Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Lentivirus, 2017?2027

Figure 15: Global Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Adenovirus, 2017?2027

Figure 16: Global Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Adeno-associated Virus (AAV), 2017?2027

Figure 17: Global Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Plasmid DNA, 2017?2027

Figure 18: Global Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Others, 2017?2027

Figure 19: Global Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by Application, 2019–2027

Figure 20: Global Viral Vector & Plasmid DNA Manufacturing Market Value Share, by Application, 2018 and 2027

Figure 21: Global Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Gene Therapy, 2017?2027

Figure 22: Global Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Vaccinology, 2017?2027

Figure 23: Global Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Others, 2017?2027

Figure 24: Global Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by Disease, 2019–2027

Figure 25: Global Viral Vector & Plasmid DNA Manufacturing Market Value Share, by Disease, 2018 and 2027

Figure 26: Global Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Genetic Disorders, 2017?2027

Figure 27: Global Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Cancer, 2017?2027

Figure 28: Global Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Infectious Diseases, 2017?2027

Figure 29: Global Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Others, 2017?2027

Figure 30: Global Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by End-user, 2019–2027

Figure 31: Global Viral Vector & Plasmid DNA Manufacturing Market Value Share, by End-user, 2018 and 2027

Figure 32: Global Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Biotech Companies, 2017?2027

Figure 33: Global Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Research Institutes, 2017?2027

Figure 34: Global Viral Vector & Plasmid DNA Manufacturing Market Value Share, by Region, for 2018 and 2027 

Figure 35: Global Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by Region, 2019–2027

Figure 36: North America Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017?2027

Figure 37: North America Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by Country, 2019–2027

Figure 38: North America Viral Vector & Plasmid DNA Manufacturing Market Value Share, by Country, 2018 and 2027

Figure 39: North America Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by Type, 2019–2027

Figure 40: North America Viral Vector & Plasmid DNA Manufacturing Market Value Share, by Type, 2018 and 2027

Figure 41: North America Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by Application, 2019–2027

Figure 42: North America Viral Vector & Plasmid DNA Manufacturing Market Value Share, by Application, 2018 and 2027

Figure 43: North America Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by Disease, 2019–2027

Figure 44: North America Viral Vector & Plasmid DNA Manufacturing Market Value Share, by Disease, 2018 and 2027

Figure 45: North America Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by End-user, 2019–2027

Figure 46: North America Viral Vector & Plasmid DNA Manufacturing Market Value Share, by End-user, 2018 and 2027

Figure 47: Europe Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017?2027

Figure 48: Europe Viral Vector & Plasmid DNA Manufacturing Market Value Share (%), by Country/Sub-region, 2018 and 2027

Figure 49: Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by Country/Sub-region, 2019–2027

Figure 50: Europe Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by Type, 2019–2027

Figure 51: Europe Viral Vector & Plasmid DNA Manufacturing Market Value Share, by Type, 2018 and 2027

Figure 52: Europe Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by Application, 2019–2027

Figure 53: Europe Viral Vector & Plasmid DNA Manufacturing Market Value Share, by Application, 2018 and 2027

Figure 54: Europe Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by Disease, 2019–2027

Figure 55: Europe Viral Vector & Plasmid DNA Manufacturing Market Value Share, by Disease, 2018 and 2027

Figure 56: Europe Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by End-user, 2019–2027

Figure 57: Europe Viral Vector & Plasmid DNA Manufacturing Market Value Share, by End-user, 2018 and 2027

Figure 58: Asia Pacific Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017?2027

Figure 59: Asia Pacific Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by Country/Sub-region, 2019–2027

Figure 60: Asia Pacific Viral Vector & Plasmid DNA Manufacturing Market Value Share, by Country/Sub-region, for 2018 and 2027

Figure 61: Asia Pacific Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by Type, 2019–2027

Figure 62: Asia Pacific Viral Vector & Plasmid DNA Manufacturing Market Value Share, by Type, 2018 and 2027

Figure 63: Asia Pacific Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by Application, 2019–2027

Figure 64: Asia Pacific Viral Vector & Plasmid DNA Manufacturing Market Value Share, by Application, 2018 and 2027

Figure 65: Asia Pacific Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by Disease, 2019–2027

Figure 66: Asia Pacific Viral Vector & Plasmid DNA Manufacturing Market Value Share, by Disease, 2018 and 2027

Figure 67: Asia Pacific Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by End-user, 2019–2027

Figure 68: Asia Pacific Viral Vector & Plasmid DNA Manufacturing Market Value Share, by End-user, 2018 and 2027

Figure 69: Latin America Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017?2027

Figure 70: Latin America Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by Country/Sub-region, 2019–2027

Figure 71: Latin America Viral Vector & Plasmid DNA Manufacturing Market Value Share, by Country/Sub-region, 2018 and 2027

Figure 72: Latin America Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by Type, 2019–2027

Figure 73: Latin America Viral Vector & Plasmid DNA Manufacturing Market Value Share, by Type, 2018 and 2027

Figure 74: Latin America Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by Application, 2019–2027

Figure 75: Latin America Viral Vector & Plasmid DNA Manufacturing Market Value Share, by Application, 2018 and 2027

Figure 76: Latin America Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by Disease, 2019–2027

Figure 77: Latin America Viral Vector & Plasmid DNA Manufacturing Market Value Share, by Disease, 2018 and 2027

Figure 78: Latin America Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by End-user, 2019–2027

Figure 79: Latin America Viral Vector & Plasmid DNA Manufacturing Market Value Share, by End-user, 2018 and 2027

Figure 80: Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017?2027

Figure 81: Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by Country/Sub-Region, 2019–2027

Figure 82: Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Market Value Share, by Country/Sub-Region, 2018 and 2027

Figure 83: Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by Type, 2019–2027

Figure 84: Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Market Value Share, by Type, 2018 and 2027

Figure 85: Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by Application, 2019–2027

Figure 86: Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Market Value Share, by Application, 2018 and 2027

Figure 87: Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by Disease, 2019–2027

Figure 88: Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Market Value Share, by Disease, 2018 and 2027

Figure 89: Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by End-user, 2019–2027

Figure 90: Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Market Value Share, by End-user, 2018 and 2027

Transparency Market Research Plus
  • We offer 100% free customisation with our Enterprise License!!
  • Get a free copy if the report you purchased is updated within 90 days
  • Regardless from where you have purchased the report, you can request an updated version of the report from us.

Complete the form below and we'll get back to you shortly.

240

Your personal details are safe with us. Privacy Policy*

Copyright © Transparency Market Research, Inc. All Rights reserved